Neuromuscular Diseases clinical trials at UC Health
3 in progress, 2 open to new patients
open to eligible people ages 18-80
The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
at UC Irvine
open to eligible males ages 5 years and up
This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
at UCSF UC Davis
“Would the study drug (CAP-1002) help improve weakened skeletal and heart muscle caused by DMD?”
Sorry, in progress, not accepting new patients
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
at UCLA UC Davis